EUCTR2022-002767-30-CZ进行中（未招募）1 期
A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)
Sanofi-aventis recherche & developpement0 个研究点目标入组 75 人开始时间: 2022年12月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •-Participants must have a documented diagnosis of multiple myeloma (MM)
- •-Participants with measurable disease defined as at least one of the following:
- •--Serum M-protein =0.5 g/dL measured using serum protein immunoelectrophoresis and/or
- •--Urine M-protein =200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
- •--Serum free light chain (FLC) assay: Involved FLC assay =10 mg/dL (=100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65).
- •-Participant with relapsed and/or refractory MM with at least 1 prior line of therapy and no more than 3 prior lines of therapy.
- •A female participant is eligible to participate if she is not pregnant, not breastfeeding, and either is not a female of childbearing potential (FCBP) or agrees to practice complete abstinence or use approved contraception methods.
- •Male participants agree to practice true abstinence or agree to use approved contraception methods while receiving study treatment, during dose interruptions and at least 3 months following study treatment discontinuation, even if has undergone a successful vasectomy.
- •Capable of giving signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 37
排除标准
- •-Primary refractory MM defined as participants who have never achieved at least a minimal response (MR) with any treatment during the disease course
- •-Participants with prior anti-CD38 treatment are excluded if: a) Progression on or within 60 days after end of anti-CD38 mAb treatment or failure to achieve at least MR to treatment (ie, refractory to anti-CD38) with a washout period inferior to 9 months before the first isatuximab administration or, b) Intolerant to the anti-CD38 previously received
- •-Prior treatment with carfilzomib
- •-Known history of allergy to captisol (a cyclodextrin derivative used to solubilize carfilzomib), prior hypersensitivity to sucrose, histidine (as base and hydrochloride salt), polysorbate 80, or any of the components (active substance or excipient) of study treatment that are not amenable to premedication with steroids, or intolerance to arginine and Poloxamer 188 that would prohibit further treatment with these agents
- •-Uncontrolled or active infection with hepatitis A, B, and C virus; known acquired immunodeficiency syndrome (AIDS)-related illness; active primary amyloid light chain (AL) amyloidosis
- •-Any severe acute or chronic medical condition which could impair the ability of the participant to participate in the study or interfere with interpretation of study results (eg, systemic infection unless specific anti-infective therapy is employed) or participant unable to comply with the study procedures.
- •The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
研究者
相似试验
招募中
1 期
A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myelomaEUCTR2022-002767-30-GRSanofi-aventis recherche & developpement75
进行中（未招募）
1 期
A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myelomaCancer - Relapsed/refractory multiple myelomaMedDRA version: 25.0Level: LLTClassification code: 10086466Term: Relapsed/refractory multiple myeloma Class: 100000004848CTIS2023-508870-27-00Sanofi-Aventis Recherche & Developpement64
招募中
2 期
A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myelomaJPRN-jRCT2031220739Tanaka Tomoyuki68
进行中（未招募）
1 期
Multicenter Clinical Trial in subjects with HER2-negative primary tumors. The subjects will be evaluated for the presence of HER2 positive Circulating Tumor Cells (CTCs) in blood. In case of at least one HER2-positive CTC in blood, the subject will be randomized to receive either (nabTM)-paclitaxel + trastuzumab (ARM A) or (nabTM)-paclitaxel (ARM B).Metastatic Breast Cancer in HER2- positive CTC with primary HER2-negative.MedDRA version: 16.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2012-005352-41-ITAZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI CREMONA86
进行中（未招募）
不适用
A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancerEUCTR2004-002391-42-HUCECOG (Central European Cooperative Oncology Group)150